Table. 1.

Baseline demographic and immunologic characteristics of study population

Variable Low-sensitized
non-DGF (n=470)
Low-sensitized
DGF (n=109)
Highly sensitized
non-DGF (n=103)
Highly sensitized
DGF (n=27)
Recipient
Age (yr) 49.8±9.8 50.5±10.0 50.1±9.8 52.6±9.1
Elderly (≥65 yr) 88 (18.7) 15 (13.8) 22 (21.4) 6 (22.2)
Male sex 297 (63.2)c) 65 (59.6)c) 45 (43.7)a),b) 12 (44.4)
BMI (kg/m2) 23.1±4.8 22.6±4.6 23.0±3.5 23.0±3.1
Dialysis vintagee) 8.1±9.5 9.2±11.6 10.0±12.2 36.8±34.9
Primary renal disease
DM 90 (19.1) 18 (16.5) 12 (11.7) 4 (14.8)
HTN 88 (18.7) 18 (16.5) 13 (12.6) 2 (7.4)
CGN 198 (42.1) 52 (47.7) 61 (59.2) 19 (70.4)
Others 94 (20.0) 21 (19.3) 17 (16.5) 2 (7.4)
History of HTN 374 (79.6)d) 90 (82.6)d) 79 (76.7) 17 (63.0)a),b)
History of DM 101 (21.5) 25 (22.9) 14 (13.6) 7 (25.9)
Previous KT 28 (6.0)c),d) 10 (9.2)c),d) 33 (32.0)a),b) 12 (44.4)a),b)
Donor
Age (yr) 46.0±14.4 45.1±14.3 45.9±14.3 45.9±13.0
Elderly (age≥ 65 yr) 88 (18.7)b) 10 (9.2)a) 13 (12.6) 3 (11.1)
Male sex 309 (65.7)c) 75 (68.8) 78 (75.7)a) 21 (77.8)
BMI (kg/m2) 23.4±3.8 23.6±3.5 23.5±3.5 23.0±3.0
HTN 99 (21.1) 21 (19.3) 15 (14.6) 3 (11.1)
DM 49 (10.4) 7 (6.4) 7 (6.8) 3 (11.1)
Cold ischemic time (hr) 4.2±2.1 4.8±2.2c) 3.9±2.1b) 4.5±2.4
SCD vs. ECDf)
SCD 318 (67.7) 80 (73.4) 78 (75.7) 21 (77.8)
ECD 152 (32.3) 29 (26.6) 25 (24.3) 6 (22.2)
AKI by KDIGO 240 (51.1)b),d) 76 (69.7)a),c) 48 (46.6)b),d) 20 (74.1)a),c)
KDPI (%) 62.8±25.9 62.9±22.2 59.0±24.5 63.5±23.1
Immunologic parameter
Mismatch number
<3 99 (21.1) 17 (15.6)d) 18 (17.5) 9 (33.3)b)
≥3 371 (78.9) 92 (84.4)d) 85 (82.5) 18 (66.7)b)
HLA-DSA 7/434 (1.6)c),d) 4/88 (4.5)c),d) 24/100 (24.0)a),b) 5/24 (20.8)a),b)
class I 2/434 (0.5)c),d) 0/88 (0.0)c),d) 9/100 (9.0)a),b) 3/24 (12.5)a),b)
class II 5/434 (1.2)b),c),d) 4/88 (4.5)a),c) 18/100 (18.0)a),b) 4/24 (16.7)a)
HLA-DSA, MFI
1,000 to <3,000 2/434 (0.5) 4/88 (4.5) 5/100 (5.0) 2/24 (8.3)
3,000 to <5,000 1/434 (0.2) 0/88 (0.0) 10/100 (10.0) 0/24 (0.0)
5,000 to <10,000 3/434 (0.7) 0/88 (0.0) 4/100 (4.0) 1/24 (4.2)
≥10,000 1/434 (0.2) 0/88 (0.0) 5/100 (5.0) 2/24 (8.3)
Mean MFI 3244.5c),d) 2401.7c),d) 7199.7a),b) 7391.4a),b)
Induction therapy
Basiliximab 336 (71.5)b),c),d) 67 (61.5)a),c) 35 (34.0)a),b) 12 (44.4)a)
ATG 134 (28.5)b),c),d) 42 (38.5)a),c) 68 (66.0)a),b) 15 (55.6)a)
Combined rituximab 2 (0.4)c),d) 1 (0.9)c),d) 41 (39.8)a),b) 7 (25.9)a),b)
Maintenance immunosuppression
Tac-MMF/Myf-steroid 468 (99.6) 107 (98.2) 103 (100.0) 27 (100.0)
CSA-MMF/Myf-steroid 2 (0.4) 1 (0.9) 0 0
SRL-MMF/Myf-steroid 0 1 (0.9) 0 0

Values are presented as mean±standard deviation or number (%). The values ​​for HLA-DSA were only for patients who had undergone HLA-DSA testing. In addition, the number of patients undergoing HLA-DSA test in each group was expressed in denominator.

DGF, delayed graft function; BMI, body mass index; DM, diabetes mellitus; HTN, hypertension; CGN, chronic glomerulonephritis; KT, kidney transplantation; SCD, standard criteria donors; ECD, expanded criteria donors; AKI, acute kidney injury; KDIGO, kidney disease improving global outcomes; KDPI, kidney donor profile index; HLA, human leukocyte antigen; DSA, donor-specific antibody; MFI, mean fluorescence intensity; ATG, antithymocyte globulin; Tac, tacrolimus; MMF, mycophenolate mofetil; Myf, mycophenolic acid; CSA, cyclosporine A; SRL, sirolimus.

a)P<0.05 vs. low-sensitized non-DGF; b)P<0.05 vs. low-sensitized DGF; c)P<0.05 vs. highly sensitized non-DGF; d)P<0.05 vs. highly sensitized DGF; e)For patients with a previous kidney transplant history, the years from the restart of dialysis to the date of kidney transplant was defined as the dialysis vintage; f)ECD was defined as all donors older than 60 years and donors older than 50 years with any two of the following criteria: (1) hypertension, (2) cerebrovascular cause of brain death, or (3) pre-retrieval serum creatinine level >1.5 mg/dL [20].

Korean J Transplant 2021;35:149~160 https://doi.org/10.4285/kjt.21.0014
© Korean Journal of Transplantation